R S Labow
Overview
Explore the profile of R S Labow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
463
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Battiston K, Labow R, Simmons C, Santerre J
Acta Biomater
. 2015 Jun;
24:74-86.
PMID: 26093069
Statement Of Significance: The ability of biomaterials to regulate macrophage activation towards a wound healing phenotype has recently been shown to support positive tissue regeneration. However, the ability of immunomodulatory...
2.
Battiston K, Ouyang B, Honarparvar E, Qian J, Labow R, Simmons C, et al.
Acta Biomater
. 2015 Jun;
24:35-43.
PMID: 26074158
Statement Of Significance: There is currently limited understanding of material design features that can regulate protein-material interactions in order to prevent adverse inflammatory responses to implanted biomaterials. In this paper,...
3.
Erfle D, Santerre J, Labow R
Cardiovasc Pathol
. 2015 May;
6(6):333-40.
PMID: 25989886
Neutrophils are the major phagocytic white blood cell present during the acute inflammatory response to cardiovascular medical devices and can become activated to release a wide variety of products that...
4.
Battiston K, Ouyang B, Labow R, Simmons C, Santerre J
Acta Biomater
. 2013 Dec;
10(3):1146-55.
PMID: 24361424
Tissue engineering strategies rely on the ability to promote cell proliferation and migration into porous biomaterial constructs, as well as to support specific phenotypic states of the cells in vitro....
5.
Santerre J, Woodhouse K, Laroche G, Labow R
Biomaterials
. 2005 Jul;
26(35):7457-70.
PMID: 16024077
After almost half a century of use in the health field, polyurethanes (PUs) remain one of the most popular group of biomaterials applied for medical devices. Their popularity has been...
6.
Ernsting M, Labow R, Santerre J
J Biomater Sci Polym Ed
. 2004 Feb;
14(12):1411-26.
PMID: 14870944
Fluorinated surface-modifying macromolecules (SMMs) have been previously reported on and shown to limit the hydrolytic degradation of polyurethanes. The SMM molecules achieve this effect by allowing for the selective migration...
7.
Tang Y, Labow R, Santerre J
Biomaterials
. 2003 May;
24(17):2805-19.
PMID: 12742719
Polycarbonate-polyurethanes (PCNUs) have provided the medical device industry with practical alternatives to oxidation-sensitive polyether-urethanes (PEUs). To date, many studies have focused on PCNUs synthesized with 4,4'-methylene diphenyl-diisocyanate (MDI). The relative...
8.
Tang Y, Labow R, Santerre J
Biomaterials
. 2003 Mar;
24(12):2003-11.
PMID: 12628819
The current study has investigated the influence of esterase activity (80-400units/ml) on the biodegradation of polycarbonate-urethanes (PCNUs) by cholesterol esterase (CE), with a particular interest in studying the influence of...
9.
Jahangir R, McCloskey C, Mc Clung W, Labow R, Brash J, Santerre J
Biomaterials
. 2002 Nov;
24(1):121-30.
PMID: 12417185
Previous investigations have demonstrated that the inflammatory cell derived enzyme, cholesterol esterase (CE) could degrade polyurethanes (PUs) by hydrolyzing ester and urethane bonds. Studies that have investigated the development of...
10.
Tang Y, Labow R, Revenko I, Santerre J
J Biomater Sci Polym Ed
. 2002 Aug;
13(4):463-83.
PMID: 12160304
Polycarbonate based polyurethanes were synthesized with varying hard segment content as well as hard segment chemistry based on three different diisocyanates,1,6-hexane diisocyanate (HDI), 4.4'-methylene bisphenyl diisocyanate (MDI) and 4,4-methylene biscyclohexyl...